◼ Archived Health Mutant KRAS vaccination for pancreatic cancer interception: the G12D immunogenicity paradox Mutant KRAS G12D vaccination emerges as a focal point for pancreatic cancer interception, with researchers probing why this specific mutation triggers immune responses that could enable preventive strategies. 3 sources 3 articles v 1 6d ago
◼ Archived Business Incyte pancreatic cancer medicine induces lasting tumor responses, company says at ESMO Incyte presents new early clinical data at ESMO for its KRAS G12D-targeted pancreatic and colorectal cancer medicine. 7 sources 7 articles v 5 20d ago
◼ Archived Business Merck licenses a KRAS G12D inhibitor for $400M upfront Merck has entered a multi-billion dollar agreement with China's SciBrunch Therapeutics to develop a preclinical KRAS G12D inhibitor. 5 sources 6 articles v 3 48d ago